Abstract:BackgroundDuchenne Muscular Dystrophy (DMD) is the most common muscle disease in children, and there are no effective therapies for DMD or Becker Muscular Dystrophy (BMD). Currently, targeted gene therapy treatments have emerged. As a result, genetic diagnosis is the basis of treatment. In addition, genetic and prenatal diagnosis significantly reduces their incidence rates. This study combines the application of multiplex ligation-dependent probe amplification technology (MLPA) and "next-generation" sequencing technology (NGS) as the most economical and efficient method of diagnosis. Therefore, in the diagnosis of DMD/BMD, patients' MLPA data are first used to detect DMD gene deletions or duplications, and NGS and Sanger sequencing are then applied to exclude MLPA-negative samples. Meanwhile, polymerase chain reaction (PCR) is used to detect single exon deletions to exclude false-positives in MLPA caused by point mutations.MethodsIn this study, we recruited 1051 proband families of DMD from 2016 to 2018 and had access to information that could identify individual participants during or after data collection. Patients who were diagnosed with DMD were first tested by MLPA. MLPA results with single exon deletions were validated with PCR amplification and Sanger sequencing. The negative results of MLPA were further analysed with NGS and validated by Sanger sequencing. For novel missense mutations, phenotype-genotype correlations were analysed using PolyPhen2 and mutation taster. All methods were performed in accordance with the relevant guidelines and regulations.ResultsDMD mutations were identified in 1029 families (97.91%, 1029/1051). Large deletions, duplications, and small mutations accounted for 70.41% (740/1051), 8.28% (87/1051), and 19.12% (201/1051) of all cases, respectively. There were 205 small mutation types, 53 of which were novel. The rate of de novo mutations was 39.45% (187/474) and was higher in large duplications (49.53%, 157/317). Among 68 asymptomatic patients (< 3 years old) with unexplained persistent hyperCKaemia upon conventional physical examination, 63 were diagnosed as DMD/BMD according to genetic diagnosis.ConclusionOur results expand the spectrum of DMD mutations, which could contribute to the treatment of DMD/BMD and provide an effective diagnosis method. Thus, the combination of MLPA, NGS and Sanger sequencing is of great significance for family analysis, gene diagnosis and gene therapy.

Comprehensive analysis of 2097 patients with dystrophinopathy based on a database from 2011 to 2021

A Comprehensive Analysis of 2013 Dystrophinopathies in China: A Report From National Rare Disease Center

A comprehensive database of Duchenne and Becker muscular dystrophy patients (0–18 years old) in East China

Genetic Identification of Pathogenic Variations of the DMD Gene: a Retrospective Study from 10,481 Neonatal Patients Based on Next-Generation Sequencing Data

A 1-Year Analysis from a Natural History Study in Chinese Individuals with Duchenne Muscular Dystrophy.

Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy

Genetic Variation Analysis and Treatment Strategy of 20 Patients with Dystrophin Gene Mutations

Comprehensive profile and natural history of pediatric patients with spinal muscular atrophy: A large retrospective study from China

Targeted Next-Generation Sequencing As a Comprehensive Test for Patients with and Female Carriers of DMD/BMD: a Multi-Population Diagnostic Study

Molecular Landscape of DYSF Mutations in Dysferlinopathy: from a Chinese Multicenter Analysis to a Worldwide Perspective.

A Comprehensive Database of Duchenne and Becker Muscular Dystrophy Patients in Children's Hospital of Fudan University

Clinical, pathological, and genetic characterization in a large Chinese cohort with female dystrophinopathy

Expanding the Molecular Genetic Landscape of Dystrophinopathies and Associated Phenotypes

Clinical Heterogeneity and a High Proportion of Novel Mutations in a Chinese Cohort of Patients with Dysferlinopathy.

Dmd Mutation Spectrum Analysis in 613 Chinese Patients with Dystrophinopathy

Longitudinal data of serum creatine kinase levels and motor, pulmonary, and cardiac functions in 337 patients with Duchenne muscular dystrophy

Clinical, Molecular Pathological and Genetic Analysis of a Chinese Family with Dystrophinopathy

Research hotspots and trends for Duchenne muscular dystrophy: a machine learning bibliometric analysis from 2004 to 2023

Genetic analysis of 1051 Chinese families with Duchenne/Becker Muscular Dystrophy

Characteristics of Dystrophin Gene Mutations among Chinese Patients As Revealed by Multiplex Ligation–Dependent Probe Amplification

Clinical Profile and Outcome of Pediatric Mitochondrial Myopathy in China